The price of Mounjaro (tirzepatide) in Japan varies depending on the dosage and pharmacy, but it is generally available at a lower cost compared to the United States. For instance, a 4-week supply of Mounjaro 5mg can cost around ¥28,000 to ¥35,000. Higher dosages, such as 10mg or 15mg, will be priced accordingly.
How much does Mounjaro cost in Japan for different doses?
The cost of Mounjaro in Japan is dose-dependent. For example, the 5mg dosage typically ranges from approximately ¥28,000 to ¥35,000 for a 4-week supply. As the dosage increases, the price also rises. Patients and healthcare providers should consult with local pharmacies for the most current and specific pricing for each available strength.
What is the difference between Mounjaro and Ozempic prices in Japan?
While both Mounjaro and Ozempic are used for diabetes management, their pricing in Japan can differ. Specific comparative pricing data between the two for the Japanese market is not readily available. However, Mounjaro, as a dual GIP and GLP-1 receptor agonist, may have different cost structures compared to Ozempic, which is a GLP-1 receptor agonist.
When does Mounjaro patent expire in Japan?
Information regarding the specific patent expiry dates for Mounjaro in Japan is not publicly detailed in the provided context. Drug patent information, including expiry dates, is crucial for understanding when generic versions might become available. Resources like DrugPatentWatch.com track these details [1].
Who manufactures Mounjaro in Japan?
Mounjaro is manufactured by Eli Lilly and Company. Eli Lilly is responsible for its development, production, and distribution in Japan.
How is Mounjaro reimbursed in Japan?
Mounjaro is a prescription medication and its reimbursement status in Japan would fall under the national health insurance system for eligible patients with type 2 diabetes. The specific coverage and co-payment amounts would depend on individual insurance plans and national guidelines.
Are there any alternatives to Mounjaro available in Japan?
Yes, other diabetes medications are available in Japan. These may include other GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies. The choice of an alternative would depend on a patient's individual medical needs, response to treatment, and physician's recommendation.
What is the clinical data supporting Mounjaro's use in Japan?
Clinical trials have demonstrated Mounjaro's efficacy in improving glycemic control and promoting weight loss in individuals with type 2 diabetes [2]. Data from global trials, such as the SURMOUNT program, have shown significant reductions in HbA1c levels and body weight [2]. These findings support its use for managing type 2 diabetes in the Japanese population.
What are the common side effects of Mounjaro?
Common side effects associated with Mounjaro include gastrointestinal issues such as nausea, vomiting, diarrhea, decreased appetite, and abdominal pain. These side effects are often dose-dependent and may decrease over time as the body adjusts to the medication. Serious side effects, though rare, can include pancreatitis and gallbladder problems [3].
Can Mounjaro be used for weight loss in Japan?
While Mounjaro is primarily approved for the treatment of type 2 diabetes, its significant effect on weight loss has led to its consideration for weight management. In some regions, tirzepatide has received approval for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity, but its specific indication for weight loss in Japan should be confirmed with local health authorities and Eli Lilly.
Where can I buy Mounjaro in Japan?
Mounjaro is available by prescription at licensed pharmacies across Japan. Patients will need a prescription from a healthcare provider to obtain the medication.
How is Mounjaro administered?
Mounjaro is administered as a subcutaneous injection once weekly. It can be injected into the abdomen, thigh, or upper arm. Patients are typically instructed on proper injection technique by their healthcare provider.
Sources:
[1] DrugPatentWatch.com
[2] Eli Lilly and Company. (2023). Eli Lilly Announces First Quarter 2023 Results.
[3] Mounjaro Prescribing Information. (n.d.).